BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Decline in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 827,800 shares, a drop of 10.2% from the November 30th total of 921,900 shares. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is presently 0.8 days.

BioLineRx Price Performance

BioLineRx stock traded up $0.00 during mid-day trading on Tuesday, hitting $0.21. 1,383,498 shares of the company were exchanged, compared to its average volume of 529,643. The company has a market capitalization of $17.11 million, a P/E ratio of -0.97 and a beta of 1.39. The business’s 50 day simple moving average is $0.33 and its two-hundred day simple moving average is $0.53. BioLineRx has a 12-month low of $0.19 and a 12-month high of $1.59. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BLRX shares. StockNews.com began coverage on BioLineRx in a research note on Thursday, December 26th. They issued a “hold” rating for the company. HC Wainwright decreased their price target on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

Hedge Funds Weigh In On BioLineRx

Hedge funds have recently made changes to their positions in the stock. PVG Asset Management Corp acquired a new position in BioLineRx during the second quarter valued at approximately $70,000. Atria Investments Inc increased its holdings in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC acquired a new stake in BioLineRx in the 2nd quarter valued at $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.